Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GPR183 | P32249 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3911482 | 0.85 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11889045 | 0.78 | HSD11B1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17868397 | 0.78 | HSD11B1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22305103 | 0.78 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6985975 | 0.78 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11888888 | 0.77 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3755574 | 0.76 | POLB (0.66) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8160260 | 0.76 | SLC6A7 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21976432 | 0.75 | PARP14 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21166248 | 0.75 | SLC6A7 (0.57) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11739071-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739071-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739071-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220033403-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2022-02-03 | — | — | US | disclosed |
| US-20220033403-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2022-02-03 | — | — | US | disclosed |
| US-20210323978-A1 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323978-A1 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2016126935-A1 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016126935-A1 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160229833-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160229833-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016126926-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016109480-A1 | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109480-A1 | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-06-30 | — | — | US | disclosed |
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-06-30 | — | — | US | disclosed |
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739071-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | USP7, UBQLN1, UBA7 | CA12 4631/4885CA1 3491/4885CA2 4508/4885 |
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | CA12 4786/4885CA1 3274/4885CA2 3885/4885 |
| US-20160229833-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBQLN1, UBA7 | CA12 4631/4885CA1 3491/4885CA2 4508/4885 |
| US-20220033403-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | CA12 4786/4885CA1 3274/4885CA2 3885/4885 |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | CA12 4786/4885CA1 3274/4885CA2 3885/4885 |
| US-20210323978-A1 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, USP3, SENP7 | CA12 4760/4885CA1 3469/4885CA2 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.